Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.88 |
| ▸ | PGR | P06401 | 5/20 | 0.88 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.88 |
| ▸ | MAPT | P10636 | 2/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.88 |
| ▸ | DRD2 | P14416 | 1/20 | 0.88 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.84 |
| ▸ | USP2 | O75604 | 5/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | MLNR | O43193 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.84 |
| ▸ | PPARG | P37231 | 1/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.84 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone Dipropionate SCHEMBL10014288 | 0.94 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL14339597 | 0.94 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL11429865 | 0.94 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL4566 | 0.94 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL20097870 | 0.94 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL13028946 | 0.94 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Dexamethasone Dipropionate SCHEMBL43107 | 0.94 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL9768468 | 0.94 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL10013893 | 0.94 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL7519 | 0.94 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 654 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4628948-A1 | POLARIZING PLATE AND OPTICAL DISPLAY DEVICE | SAMSUNG SDI CO., LTD. (KR) | 2025-10-08 | — | — | EP | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| WO-2024117660-A1 | POLARIZING PLATE AND OPTICAL DISPLAY DEVICE | 삼성에스디아이 주식회사 | 2024-06-06 | — | — | WO | claimed |
| US-20230381102-A1 | RINSE-OFF COMPOSITIONS AND USES THEREOF FOR DELIVERY OF ACTIVE AGENTS | CRESCITA THERAPEUTICS INC. (CA) | 2023-11-30 | — | — | US | claimed |
| US-20220096498-A1 | INJECTABLE SUSTAINED-RELEASE FORMULATIONS FOR TREATMENT OF JOINT PAIN AND INFLAMMATION | FORDOZ PHARMA CORP. (US) | 2022-03-31 | — | — | US | claimed |
| EP-3937905-A1 | RINSE-OFF COMPOSITIONS AND USES THEREOF FOR DELIVERY OF ACTIVE AGENTS | Crescita Therapeutics Inc. (CA) | 2022-01-19 | — | — | EP | claimed |
| US-20210169800-A1 | RINSE-OFF COMPOSITIONS AND USES THEREOF FOR DELIVERY OF ACTIVE AGENTS | CRESCITA THERAPEUTICS INC. (CA) | 2021-06-10 | — | — | US | claimed |
| WO-2020227353-A1 | INJECTABLE SUSTAINED-RELEASE FORMULATIONS FOR TREATMENT OF JOINT PAIN AND INFLAMMATION | FORDOZ PHARMA CORP. (US) | 2020-11-12 | — | — | WO | claimed |
| WO-2020181395-A1 | RINSE-OFF COMPOSITIONS AND USES THEREOF FOR DELIVERY OF ACTIVE AGENTS | CRESCITA THERAPEUTICS INC. (CA) | 2020-09-17 | — | — | WO | claimed |
| US-20200289415-A1 | RINSE-OFF COMPOSITIONS AND USES THEREOF FOR DELIVERY OF ACTIVE AGENTS | CRESCITA THERAPEUTICS INC. (CA) | 2020-09-17 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1948167-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2008-07-30 | — | — | EP | claimed |
| WO-2008023336-A2 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-02-28 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007045980-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289415-A1 | RINSE-OFF COMPOSITIONS AND USES THEREOF FOR DELIVERY OF ACTIVE AGENTS | PLOD3, DSG1, POLR1C | NR3C1 3473/4885PGR 2047/4885NR1I2 3812/4885 |
| US-20210169800-A1 | RINSE-OFF COMPOSITIONS AND USES THEREOF FOR DELIVERY OF ACTIVE AGENTS | PLOD3, DSG1, POLR1C | NR3C1 3473/4885PGR 2047/4885NR1I2 3812/4885 |
| US-20230381102-A1 | RINSE-OFF COMPOSITIONS AND USES THEREOF FOR DELIVERY OF ACTIVE AGENTS | PLOD3, DSG1, POLR1C | NR3C1 3473/4885PGR 2047/4885NR1I2 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.